NeuroVive Pharmaceutical - Interim report January-June 2016

Business operations
Important events April-June 2016

  · Fully subscribed rights issue amounting to approximately SEK 77.3 million
after issue expenses
  · A preclinical TBI program initiated together with PENN
  · NeuroVive’s share upgraded for trading on OTCQX Best Market in the US
  · The clinical Phase II study CiPRICS fully recruited with 150 patients

Events after the end of the period

  ·  NeuroVive received a purported notice of termination of licensing agreement
from Arbutus Biopharma
  · NeuroVive’s novel strategy for treatment of mitochondrial disease published
in Nature Communications
  · NeuroVive completed 10 percent acquisition of Isomerase Therapeutics

Financial information

Second Quarter (April - June 2016)

  · Net revenues were SEK 0 (2,502,000) and other operating income was SEK
28,000 (377,000)
  · Loss before tax was SEK 12,059,000 (15,216,000)
  · Earnings per share* were SEK -0.34 (-0.54)
  · Diluted earnings per share** were SEK -0.34 (-0.54)

First six months (January - June 2016)

  · Net revenues were SEK 0 (2,502,000) and other operating income was SEK
74,000 (426,000)
  · Loss before tax was SEK 22,487,000 (29,487,000)
  · Earnings per share* were SEK -0.64 (-1.02)
  · Diluted earnings per share** were SEK -0.64 (-1.02)

* Profit/loss for the period divided by the average number of shares before
dilution at the end of the period.
**Profit/loss for the period divided by the average number of shares after
dilution at the end of the period.

Read the complete Interim report attached below.

About NeuroVive

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) is a pioneer
in mitochondrial medicine and a company committed to the discovery and
development of highly targeted candidates that preserve mitochondrial integrity
and function in areas of significant therapeutic need. NeuroVive's business
approach is driven by value-adding partnerships with mitochondrial research
institutions and commercial partners across the globe.

NeuroVive's portfolio consists of two clinical projects, one in acute kidney
injury (CicloMulsion®) and one in traumatic brain injury (NeuroSTAT®). The
candidate drug NeuroSTAT has orphan drug designation in Europe and in the US for
treatment of moderate to severe traumatic brain injury and is currently being
evaluated in the CHIC study. CicloMulsion is being evaluated in an on-going
study, CiPRICS, in acute kidney injury during major surgery. Furthermore, the
R&D portfolio consists of two late stage discovery programs and one compound in
preclinical development.

NeuroVive is listed on Nasdaq Stockholm, Sweden, Small Cap, under the ticker
symbol NVP. The share is also traded on the OTC Markets Group Inc market in the
US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund
Tel: +46-46 275 62 20 (switchboard)
ir@neurovive.com
www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation and the
Securities Markets Act. The information was submitted for publication, through
the agency of the contact person set out above, at 08:30 a.m. CET on August 18,
2016.